The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis

[1]  T. Miyake,et al.  c-Src modulates ErbB2 and ErbB3 heterocomplex formation and function , 2007, Oncogene.

[2]  B. Neel,et al.  Protein-tyrosine phosphatase 1B is required for HER2/Neu-induced breast cancer. , 2007, Cancer research.

[3]  V. Durbecq,et al.  The 17q12-q21 amplicon: Her2 and topoisomerase-IIalpha and their importance to the biology of solid tumours. , 2007, Cancer treatment reviews.

[4]  S. Batra,et al.  MUC4 expression correlates with poor prognosis in small-sized lung adenocarcinoma. , 2007, Lung cancer.

[5]  齋藤 幸.  MUC4 expression is a novel prognostic factor in patients with invasive ductal carcinoma of the pancreas , 2007 .

[6]  J. Mackey,et al.  Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  P. Escobar,et al.  A data model to predict HER2 status in breast cancer based on the clinical and pathologic profiles of a large patient population at a single institution. , 2006, Breast.

[8]  C. Dive,et al.  Activated c-SRC in ductal carcinoma in situ correlates with high tumour grade, high proliferation and HER2 positivity , 2006, British Journal of Cancer.

[9]  Marissa E. Nolan,et al.  Par6–aPKC uncouples ErbB2 induced disruption of polarized epithelial organization from proliferation control , 2006, Nature Cell Biology.

[10]  Z. Xiang,et al.  Loss of Hsp90 Association Up-Regulates Src-Dependent ErbB2 Activity , 2006, Molecular and Cellular Biology.

[11]  G. Inghirami,et al.  β4 Integrin Amplifies ErbB2 Signaling to Promote Mammary Tumorigenesis , 2006, Cell.

[12]  S. Batra,et al.  MUC4 Is a Novel Prognostic Factor of Extrahepatic Bile Duct Carcinoma , 2006, Clinical Cancer Research.

[13]  Cary Lai,et al.  The Mucin Muc4 Potentiates Neuregulin Signaling by Increasing the Cell-surface Populations of ErbB2 and ErbB3* , 2006, Journal of Biological Chemistry.

[14]  Carlos L Arteaga,et al.  HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. , 2006, Cancer cell.

[15]  C. Tomasetto,et al.  MLN64 and MENTHO, two mediators of endosomal cholesterol transport. , 2006, Biochemical Society transactions.

[16]  C. Morrison,et al.  HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  S. Muthuswamy,et al.  Controlled activation of ErbB1/ErbB2 heterodimers promote invasion of three-dimensional organized epithelia in an ErbB1-dependent manner: implications for progression of ErbB2-overexpressing tumors. , 2006, Cancer research.

[18]  Sehwan Han,et al.  HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry , 2006, Histopathology.

[19]  J. Terwilliger,et al.  Prostatic intraepithelial neoplasia and adenocarcinoma in mice expressing a probasin-Neu oncogenic transgene. , 2006, Carcinogenesis.

[20]  Jan G. Hengstler,et al.  ERBB2-Mediated Transcriptional Up-regulation of the α5β1 Integrin Fibronectin Receptor Promotes Tumor Cell Survival Under Adverse Conditions , 2006 .

[21]  M. Campiglio,et al.  Role of exon-16-deleted HER2 in breast carcinomas. , 2006, Endocrine-related cancer.

[22]  P. Kauraniemi,et al.  Activation of multiple cancer-associated genes at the ERBB2 amplicon in breast cancer. , 2006, Endocrine-related cancer.

[23]  E. Tokunaga,et al.  Akt is frequently activated in HER2/neu‐positive breast cancers and associated with poor prognosis among hormone‐treated patients , 2006, International journal of cancer.

[24]  W. Park,et al.  Somatic Mutations of ERBB2 Kinase Domain in Gastric, Colorectal, and Breast Carcinomas , 2006, Clinical Cancer Research.

[25]  U. Şahin,et al.  ERBB2-mediated transcriptional up-regulation of the alpha5beta1 integrin fibronectin receptor promotes tumor cell survival under adverse conditions. , 2006, Cancer research.

[26]  S. Muthuswamy,et al.  Controlled Activation of ErbB 1 / ErbB 2 Heterodimers Promote Invasion of Three-Dimensional Organized Epithelia in an ErbB 1-Dependent Manner : Implications for Progression of ErbB 2-Overexpressing Tumors , 2006 .

[27]  T. Yano,et al.  Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. , 2006, Oncology reports.

[28]  W. Muller,et al.  The c-Src tyrosine kinase associates with the catalytic domain of ErbB-2: implications for ErbB-2 mediated signaling and transformation , 2005, Oncogene.

[29]  S. Rane,et al.  Cyclin-dependent kinase 4 expression is essential for neu-induced breast tumorigenesis. , 2005, Cancer research.

[30]  Su Jie,et al.  FAK signaling is critical for ErbB-2/ErbB-3 receptor cooperation for oncogenic transformation and invasion , 2005, The Journal of cell biology.

[31]  J. Gray,et al.  Copy number aberrations in mouse breast tumors reveal loci and genes important in tumorigenic receptor tyrosine kinase signaling. , 2005, Cancer research.

[32]  R. Cardiff,et al.  HER2/neu-induced mammary tumorigenesis and angiogenesis are reduced in cyclooxygenase-2 knockout mice. , 2005, Cancer research.

[33]  C. Perou,et al.  Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. , 2005, Cancer research.

[34]  W. Gullick,et al.  The epidermal growth factor receptor family. , 2005, Endocrine-related cancer.

[35]  M. Mann,et al.  Phosphotyrosine interactome of the ErbB-receptor kinase family , 2005, Molecular systems biology.

[36]  M. Hung,et al.  A hypoxia-independent hypoxia-inducible factor-1 activation pathway induced by phosphatidylinositol-3 kinase/Akt in HER2 overexpressing cells. , 2005, Cancer research.

[37]  H. Fujii,et al.  Frequencies of HER-2/neu expression and gene amplification in patients with oesophageal squamous cell carcinoma , 2005, British Journal of Cancer.

[38]  Raymond R Tubbs,et al.  Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization: a technical review with interpretive guidelines. , 2005, Human pathology.

[39]  J. Minna,et al.  Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. , 2005, Cancer research.

[40]  Dihua Yu,et al.  ErbB2 promotes Src synthesis and stability: novel mechanisms of Src activation that confer breast cancer metastasis. , 2005, Cancer research.

[41]  E. Andrechek,et al.  Targeted disruption of ErbB2/Neu in the mammary epithelium results in impaired ductal outgrowth , 2005, Oncogene.

[42]  W. Muller,et al.  ErbB2 overexpression in mammary cells upregulates VEGF through the core promoter. , 2005, Biochemical and biophysical research communications.

[43]  C. Osborne,et al.  Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu , 1992, Breast Cancer Research and Treatment.

[44]  L. Skoog,et al.  Role of cyclin D1 in ErbB2-positive breast cancer and tamoxifen resistance , 2005, Breast Cancer Research and Treatment.

[45]  Alison M Dunning,et al.  Common ERBB2 polymorphisms and risk of breast cancer in a white British population: a case–control study , 2005, Breast Cancer Research.

[46]  V. Kosma,et al.  Expression of Matrix Metalloproteinase (MMP)-2 and MMP-9 in Breast Cancer with a Special Reference to Activator Protein-2, HER2, and Prognosis , 2004, Clinical Cancer Research.

[47]  G. Hortobagyi,et al.  Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. , 2004, Cancer cell.

[48]  S. Loibl,et al.  Silencing of the HER2/neu gene by siRNA inhibits proliferation and induces apoptosis in HER2/neu-overexpressing breast cancer cells. , 2004, Neoplasia.

[49]  Terry L. Smith,et al.  Activation of the Akt/Mammalian Target of Rapamycin/4E-BP1 Pathway by ErbB2 Overexpression Predicts Tumor Progression in Breast Cancers , 2004, Clinical Cancer Research.

[50]  Andrew D. Yates,et al.  Athletics: Momentous sprint at the 2156 Olympics? , 2004, Nature.

[51]  M. Hung,et al.  Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2. , 2004, Cancer cell.

[52]  M. Lemmon,et al.  ErbB3/HER3 does not homodimerize upon neuregulin binding at the cell surface , 2004, FEBS letters.

[53]  K. Wester,et al.  HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review , 2004, British Journal of Cancer.

[54]  K. Makino,et al.  Upregulation of IKKα/IKKβ by integrin-linked kinase is required for HER2/neu-induced NF-κB antiapoptotic pathway , 2004, Oncogene.

[55]  H. Koeppen,et al.  HER2-Targeted Therapy Reduces Incidence and Progression of Midlife Mammary Tumors in Female Murine Mammary Tumor Virus huHER2-Transgenic Mice , 2004, Clinical Cancer Research.

[56]  David N Louis,et al.  The role of the cyclin D1-dependent kinases in ErbB2-mediated breast cancer. , 2004, The American journal of pathology.

[57]  Joshua LaBaer,et al.  Cooperation of the ErbB2 receptor and transforming growth factor beta in induction of migration and invasion in mammary epithelial cells. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[58]  Kohzoh Imai,et al.  MUC4 is a novel prognostic factor of intrahepatic cholangiocarcinoma‐mass forming type , 2004, Hepatology.

[59]  R. Janknecht,et al.  Upregulation of the Catalytic Telomerase Subunit by the Transcription Factor ER81 and Oncogenic HER2/Neu, Ras, or Raf , 2004, Molecular and Cellular Biology.

[60]  William R. Sellers,et al.  PI3K/PTEN/Akt Pathway , 2004 .

[61]  C. J. Barnes,et al.  Biology of the epidermal growth factor receptor family. , 2004, Cancer treatment and research.

[62]  B. Seliger,et al.  Small interfering RNA (siRNA) inhibits the expression of the Her2/neu gene, upregulates HLA class I and induces apoptosis of Her2/neu positive tumor cell lines , 2004, International journal of cancer.

[63]  K. Makino,et al.  Upregulation of IKKalpha/IKKbeta by integrin-linked kinase is required for HER2/neu-induced NF-kappaB antiapoptotic pathway. , 2004, Oncogene.

[64]  H. Lane,et al.  Myc and Mammary Cancer: Myc is a Downstream Effector of the ErbB2 Receptor Tyrosine Kinase , 2004, Journal of Mammary Gland Biology and Neoplasia.

[65]  Päivikki Kauraniemi,et al.  Amplification of a 280-kilobase core region at the ERBB2 locus leads to activation of two hypothetical proteins in breast cancer. , 2003, The American journal of pathology.

[66]  Thomas Beckers,et al.  Switching off HER-2/neu in a tetracycline-controlled mouse tumor model leads to apoptosis and tumor-size-dependent remission. , 2003, Cancer research.

[67]  Douglas Lauffenburger,et al.  HER2-mediated effects on EGFR endosomal sorting: analysis of biophysical mechanisms. , 2003, Biophysical journal.

[68]  L. Cantley,et al.  Targeting the PI3K-Akt pathway in human cancer: rationale and promise. , 2003, Cancer cell.

[69]  D. Gertig,et al.  The HER2 I655V polymorphism and risk of breast cancer in women < age 40 years. , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[70]  K. Grigor,et al.  HER2/neu overexpression in the development of muscle-invasive transitional cell carcinoma of the bladder , 2003, British Journal of Cancer.

[71]  M. Sliwkowski,et al.  An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. , 2003, Molecular cell.

[72]  A. Citri,et al.  Polar expression of ErbB-2/HER2 in epithelia. Bimodal regulation by Lin-7. , 2003, Developmental cell.

[73]  R. Janknecht,et al.  Acetylation-Mediated Transcriptional Activation of the ETS Protein ER81 by p300, P/CAF, and HER2/Neu , 2003, Molecular and Cellular Biology.

[74]  C. A. Carraway,et al.  Muc4/Sialomucin Complex, the Intramembrane ErbB2 Ligand, Translocates ErbB2 to the Apical Surface in Polarized Epithelial Cells* , 2003, Journal of Biological Chemistry.

[75]  K. Bloom,et al.  The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. , 2003, The oncologist.

[76]  F. Maurer,et al.  The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[77]  D. Lauffenburger,et al.  Quantitative Analysis of HER2-mediated Effects on HER2 and Epidermal Growth Factor Receptor Endocytosis , 2003, Journal of Biological Chemistry.

[78]  A. Sahin,et al.  Heregulin and HER2 signaling selectively activates c‐Src phosphorylation at tyrosine 215 , 2003, FEBS letters.

[79]  Göran Landberg,et al.  C-erbB2, p27 and G1/S aberrations in human primary breast cancer. , 2003, Anticancer research.

[80]  R. Gelber,et al.  Decreased immunoreactivity for p27 protein in patients with early‐stage breast carcinoma is correlated with HER‐2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status , 2003, Cancer.

[81]  J. Koland,et al.  Roles of mitogen-activated protein kinase and phosphoinositide 3'-kinase in ErbB2/ErbB3 coreceptor-mediated heregulin signaling. , 2003, Experimental cell research.

[82]  P. Sternberg,et al.  The epidermal growth factor system in Caenorhabditis elegans. , 2003, Experimental cell research.

[83]  S. Ethier,et al.  p38MAPK induces cell surface alpha4 integrin downregulation to facilitate erbB-2-mediated invasion. , 2003, Neoplasia.

[84]  M. Sliwkowski.  Ready to partner , 2003, Nature Structural Biology.

[85]  A. M. Stanley,et al.  Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab , 2003, Nature.

[86]  Michael Kofler,et al.  The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. , 2003, Molecular cell.

[87]  William R Sellers,et al.  PI3K/PTEN/AKT pathway. A critical mediator of oncogenic signaling. , 2003, Cancer treatment and research.

[88]  T. Hunter,et al.  The Protein Kinase Complement of the Human Genome , 2002, Science.

[89]  Sarel J. Fleishman,et al.  A putative molecular-activation switch in the transmembrane domain of erbB2 , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[90]  Mitchell D Schnall,et al.  Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis. , 2002, Cancer cell.

[91]  F. O'Malley,et al.  The Role of HER2/neu Overexpression/Amplification in the Progression of Ductal Carcinoma In Situ to Invasive Carcinoma of the Breast , 2002, Modern Pathology.

[92]  John F Timms,et al.  Effects of ErbB-2 overexpression on mitogenic signalling and cell cycle progression in human breast luminal epithelial cells , 2002, Oncogene.

[93]  Alfonso Bellacosa,et al.  Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27Kip1 by PKB/Akt-mediated phosphorylation in breast cancer , 2002, Nature Medicine.

[94]  Carlos L. Arteaga,et al.  PKB/Akt mediates cell-cycle progression by phosphorylation of p27Kip1 at threonine 157 and modulation of its cellular localization , 2002, Nature Medicine.

[95]  I. Weinstein.  Addiction to Oncogenes--the Achilles Heal of Cancer , 2002, Science.

[96]  S. Luoh.  Amplification and expression of genes from the 17q11∼q12 amplicon in breast cancer cells , 2002 .

[97]  C. Sawyers,et al.  The phosphatidylinositol 3-Kinase–AKT pathway in human cancer , 2002, Nature Reviews Cancer.

[98]  R. Neve,et al.  ErbB2 Activation of ESX gene expression , 2002, Oncogene.

[99]  L. Norton,et al.  Cyclooxygenase-2 Is Overexpressed in HER-2/neu-positive Breast Cancer , 2002, The Journal of Biological Chemistry.

[100]  F. Hirsch,et al.  Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas , 2002, British Journal of Cancer.

[101]  Benjamin D. Smith,et al.  Characterization of the HER-2/neu oncogene by immunohistochemical and fluorescence in situ hybridization analysis in oral and oropharyngeal squamous cell carcinoma. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[102]  N. Kenney,et al.  Suppression of Neu-induced mammary tumor growth in cyclin D1 deficient mice is compensated for by cyclin E , 2002, Oncogene.

[103]  S. Luoh.  Amplification and expression of genes from the 17q11 approximately q12 amplicon in breast cancer cells. , 2002, Cancer genetics and cytogenetics.

[104]  J. Slingerland,et al.  PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest , 2002, Nature Medicine.

[105]  H. Tsuda,et al.  Detection of HER‐2/neu (c‐erb B‐2) DNA amplification in primary breast carcinoma , 2001, Cancer.

[106]  M. Piccart,et al.  An overview of HER2. , 2001, Seminars in oncology.

[107]  O. Monni,et al.  New amplified and highly expressed genes discovered in the ERBB2 amplicon in breast cancer by cDNA microarrays. , 2001, Cancer research.

[108]  W. Muller,et al.  The pea3 subfamily ets genes are required for HER2/Neu-mediated mammary oncogenesis , 2001, Current Biology.

[109]  N. Hellyer,et al.  Heregulin-dependent Activation of Phosphoinositide 3-Kinase and Akt via the ErbB2/ErbB3 Co-receptor* , 2001, The Journal of Biological Chemistry.

[110]  J. Slingerland,et al.  Constitutive MEK/MAPK Activation Leads to p27Kip1Deregulation and Antiestrogen Resistance in Human Breast Cancer Cells* , 2001, The Journal of Biological Chemistry.

[111]  N. Yoshimi,et al.  Constitutive expression of ErbB-2 in gallbladder epithelium results in development of adenocarcinoma. , 2001, Cancer research.

[112]  Alfonso Bellacosa,et al.  AKT plays a central role in tumorigenesis , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[113]  N. Hynes,et al.  Mammary glands reconstituted with Neu/ErbB2 transformed HC11 cells provide a novel orthotopic tumor model for testing anti-cancer agents , 2001, Oncogene.

[114]  M. Bissell,et al.  ErbB2, but not ErbB1, reinitiates proliferation and induces luminal repopulation in epithelial acini , 2001, Nature Cell Biology.

[115]  A. Lenferink,et al.  ErbB2/neu kinase modulates cellular p27(Kip1) and cyclin D1 through multiple signaling pathways. , 2001, Cancer research.

[116]  Y. Geng,et al.  Specific protection against breast cancers by cyclin D1 ablation , 2001, Nature.

[117]  M. Hung,et al.  p27 Kip1 inhibits HER2/neu-mediated cell growth and tumorigenesis , 2001, Oncogene.

[118]  G. Semenza,et al.  HER2 (neu) Signaling Increases the Rate of Hypoxia-Inducible Factor 1α (HIF-1α) Synthesis: Novel Mechanism for HIF-1-Mediated Vascular Endothelial Growth Factor Expression , 2001, Molecular and Cellular Biology.

[119]  S. Parsons,et al.  Src family kinases and HER2 interactions in human breast cancer cell growth and survival , 2001, Oncogene.

[120]  H. Kosmehl,et al.  Elevated activity and expression of Src-family kinases in human breast carcinoma tissue versus matched non-tumor tissue , 2001, Journal of Cancer Research and Clinical Oncology.

[121]  M. Hung,et al.  Correlation of p27 protein expression with HER‐2/neu expression in breast cancer , 2001, Molecular carcinogenesis.

[122]  A. Ullrich,et al.  The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. , 2001, Endocrine-related cancer.

[123]  T. Mcclanahan,et al.  Involvement of chemokine receptors in breast cancer metastasis , 2001, Nature.

[124]  T. Vartanian,et al.  Neuregulin-Induced Association of Sos Ras Exchange Protein with HER2(erbB2)/HER3(erbB3) Receptor Complexes in Schwann Cells through a Specific Grb2-HER2(erbB2) Interaction , 2001, Developmental Neuroscience.

[125]  Y. Yarden,et al.  Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.

[126]  S. Edge,et al.  Breast cancer risk factors and HER2 over-expression in tumors. , 2001, Cancer detection and prevention.

[127]  John Mendelsohn,et al.  The EGF receptor family as targets for cancer therapy , 2000, Oncogene.

[128]  J. Jorcano,et al.  Constitutive expression of erbB2 in epidermis of transgenic mice results in epidermal hyperproliferation and spontaneous skin tumor development , 2000, Oncogene.

[129]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[130]  M. Hung,et al.  Oncogenic Signals of HER-2/neu in Regulating the Stability of the Cyclin-dependent Kinase Inhibitor p27* , 2000, The Journal of Biological Chemistry.

[131]  Monilola A. Olayioye,et al.  The ErbB signaling network: receptor heterodimerization in development and cancer , 2000, The EMBO journal.

[132]  D. Birnbaum,et al.  ERBIN: a basolateral PDZ protein that interacts with the mammalian ERBB2/HER2 receptor , 2000, Nature Cell Biology.

[133]  P. Sternberg,et al.  Regulation of EGF receptor signaling in the fruitfly D. melanogaster and the nematode C. elegans. , 2000, Breast disease.

[134]  G. Fischbach,et al.  Neuregulin induces the rapid association of focal adhesion kinase with the erbB2-erbB3 receptor complex in schwann cells. , 2000, Biochemical and biophysical research communications.

[135]  A. Sacchi,et al.  Cooperative Signaling between α6β4Integrin and ErbB-2 Receptor Is Required to Promote Phosphatidylinositol 3-Kinase-dependent Invasion* , 2000, The Journal of Biological Chemistry.

[136]  X. Shu,et al.  Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk. , 2000, Journal of the National Cancer Institute.

[137]  J. Drebin,et al.  Down-regulation of HER2/neu expression induces apoptosis in human cancer cells that overexpress HER2/neu. , 2000, Cancer research.

[138]  S. Ethier,et al.  ERBB-2 overexpression confers PI 3 ′ kinase-dependent invasion capacity on human mammary epithelial cells , 2000, British Journal of Cancer.

[139]  Y. Yarden,et al.  Cyclin D1 Is Required for Transformation by Activated Neu and Is Induced through an E2F-Dependent Signaling Pathway , 2000, Molecular and Cellular Biology.

[140]  P. Leder,et al.  A Mouse Model for Breast Cancer Induced by Amplification and Overexpression of the neu Promoter and Transgene , 2000, Molecular medicine.

[141]  M. Rudnicki,et al.  Amplification of the neu/erbB-2 oncogene in a mouse model of mammary tumorigenesis. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[142]  S. Devries,et al.  Genetic alterations in ERBB2-amplified breast carcinomas. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[143]  K. Barrett,et al.  ErbB2 and ErbB3 Receptors Mediate Inhibition of Calcium-dependent Chloride Secretion in Colonic Epithelial Cells* , 1999, The Journal of Biological Chemistry.

[144]  J. Brugge,et al.  Controlled Dimerization of ErbB Receptors Provides Evidence for Differential Signaling by Homo- and Heterodimers , 1999, Molecular and Cellular Biology.

[145]  R. Epstein,et al.  Overexpression of ErbB2 impairs ligand‐dependent downregulation of epidermal growth factor receptors via a post‐transcriptional mechanism , 1999, Journal of cellular biochemistry.

[146]  A. Paterson,et al.  Conditional expression of the ErbB2 oncogene elicits reversible hyperplasia in stratified epithelia and up-regulation of TGFα expression in transgenic mice , 1999, Oncogene.

[147]  Kuo-Fen Lee,et al.  Rescue of the Cardiac Defect in ErbB2 Mutant Mice Reveals Essential Roles of ErbB2 in Peripheral Nervous System Development , 1999, Neuron.

[148]  P. Jolicoeur,et al.  Elevated frequency of loss of heterozygosity in mammary tumors arising in mouse mammary tumor virus/neu transgenic mice. , 1999, Cancer research.

[149]  T. K. Yeung,et al.  Endocytosis deficiency of epidermal growth factor (EGF) receptor-ErbB2 heterodimers in response to EGF stimulation. , 1999, Molecular biology of the cell.

[150]  R. Cardiff,et al.  Elevated expression of activated forms of Neu/ErbB‐2 and ErbB‐3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer , 1999, The EMBO journal.

[151]  C. A. Carraway,et al.  An Intramembrane Modulator of the ErbB2 Receptor Tyrosine Kinase That Potentiates Neuregulin Signaling* , 1999, The Journal of Biological Chemistry.

[152]  M. Mandal,et al.  Regulation of Cyclooxygenase-2 pathway by HER2 receptor , 1999, Oncogene.

[153]  M. Hung,et al.  A novel splice variant of HER2 with increased transformation activity , 1998, Molecular carcinogenesis.

[154]  L. Sheffield.  C-Src activation by ErbB2 leads to attachment-independent growth of human breast epithelial cells. , 1998, Biochemical and biophysical research communications.

[155]  N. Hellyer,et al.  Signal transduction by epidermal growth factor and heregulin via the kinase-deficient ErbB3 protein. , 1998, The Biochemical journal.

[156]  D. Riethmacher,et al.  The ErbB2 and ErbB3 receptors and their ligand, neuregulin-1, are essential for development of the sympathetic nervous system. , 1998, Genes & development.

[157]  A. Lenferink,et al.  Differential endocytic routing of homo‐ and hetero‐dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers , 1998, The EMBO journal.

[158]  B. Geiger,et al.  Alternative Intracellular Routing of ErbB Receptors May Determine Signaling Potency* , 1998, The Journal of Biological Chemistry.

[159]  A. Paterson,et al.  Targeted expression of activated erbB-2 to the epidermis of transgenic mice elicits striking developmental abnormalities in the epidermis and hair follicles. , 1998, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[160]  P. Leder,et al.  Signal transduction pathways activated and required for mammary carcinogenesis in response to specific oncogenes , 1998, Oncogene.

[161]  E. Wagner,et al.  A strain‐independent postnatal neurodegeneration in mice lacking the EGF receptor , 1998, The EMBO journal.

[162]  J. Jorcano,et al.  Severe follicular hyperplasia and spontaneous papilloma formation in transgenic mice expressing the neu oncogene under the control of the bovine keratin 5 promoter , 1998, Molecular carcinogenesis.

[163]  G. Frantz,et al.  ErbB3 is required for normal cerebellar and cardiac development: a comparison with ErbB2-and heregulin-deficient mice. , 1997, Development.

[164]  H. Juhl,et al.  HER-2/neu Is Rate-limiting for Ovarian Cancer Growth , 1997, The Journal of Biological Chemistry.

[165]  A. Paterson,et al.  Targeted expression of a dominant negative epidermal growth factor receptor in the mammary gland of transgenic mice inhibits pubertal mammary duct development. , 1997, Molecular endocrinology.

[166]  D. Riethmacher,et al.  Severe neuropathies in mice with targeted mutations in the ErbB3 receptor , 1997, Nature.

[167]  M. Crescenzi,et al.  α6β4 and α6β1 Integrins Associate with ErbB-2 in Human Carcinoma Cell Lines , 1997 .

[168]  S. Ritland,et al.  Loss of heterozygosity analysis in primary mammary tumors and lung metastases of MMTV-MTAg and MMTV-neu transgenic mice. , 1997, Cancer research.

[169]  B. Li,et al.  neu/ERBB2 cooperates with p53-172H during mammary tumorigenesis in transgenic mice , 1997, Molecular and cellular biology.

[170]  N. Hynes,et al.  ErbB‐2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling , 1997, The EMBO journal.

[171]  P. W. Janes,et al.  Structural Determinants of the Interaction between the erbB2 Receptor and the Src Homology 2 Domain of Grb7* , 1997, The Journal of Biological Chemistry.

[172]  H. Kim,et al.  Biochemical characterization of the protein tyrosine kinase homology domain of the ErbB3 (HER3) receptor protein. , 1997, The Biochemical journal.

[173]  M. Crescenzi,et al.  Alpha 6 beta 4 and alpha 6 beta 1 integrins associate with ErbB-2 in human carcinoma cell lines. , 1997, Experimental cell research.

[174]  Y. Yarden,et al.  A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor , 1996, Molecular and cellular biology.

[175]  H. von Melchner,et al.  Reversible tumorigenesis in mice by conditional expression of the HER2/c-erbB2 receptor tyrosine kinase. , 1996, Oncogene.

[176]  W. Muller,et al.  Mutations affecting conserved cysteine residues within the extracellular domain of Neu promote receptor dimerization and activation. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[177]  P. Meltzer,et al.  Independent amplification and frequent co-amplification of three nonsyntenic regions on the long arm of chromosome 20 in human breast cancer. , 1996, Cancer research.

[178]  S. Ethier,et al.  Phosphatidylinositol 3-kinase recruitment by p185erbB-2 and erbB-3 is potently induced by neu differentiation factor/heregulin during mitogenesis and is constitutively elevated in growth factor-independent breast carcinoma cells with c-erbB-2 gene amplification. , 1996, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[179]  G. Carpenter,et al.  All ErbB Receptors Other Than the Epidermal Growth Factor Receptor Are Endocytosis Impaired (*) , 1996, The Journal of Biological Chemistry.

[180]  D. Curiel,et al.  Intracellular antibody against erbB-2 mediates targeted tumor cell eradication by apoptosis. , 1996, Cancer gene therapy.

[181]  Y. Yarden,et al.  ErbB‐2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. , 1996, The EMBO journal.

[182]  Kuo-Fen Lee,et al.  Requirement for neuregulin receptor erbB2 in neural and cardiac development , 1995, Nature.

[183]  Rüdiger Klein,et al.  Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor , 1995, Nature.

[184]  W. Muller,et al.  Activation of Src family kinases in Neu-induced mammary tumors correlates with their association with distinct sets of tyrosine phosphorylated proteins in vivo. , 1995, Oncogene.

[185]  T. Arakawa,et al.  Binding of Neu Differentiation Factor with the Extracellular Domain of Her2 and Her3 (*) , 1995, The Journal of Biological Chemistry.

[186]  A. Ullrich,et al.  Heregulin‐dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3. , 1995, The EMBO journal.

[187]  R. Derynck,et al.  Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor , 1995, Nature.

[188]  W. Muller,et al.  Direct and specific interaction of c-Src with Neu is involved in signaling by the epidermal growth factor receptor. , 1995, Oncogene.

[189]  K. Herrup,et al.  Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype. , 1995, Science.

[190]  E. Wagner,et al.  Strain-dependent epithelial defects in mice lacking the EGF receptor. , 1995, Science.

[191]  M. Kraus,et al.  Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. , 1995, Oncogene.

[192]  H. Fujita.  [Anticancer drugs]. , 1995, Nihon rinsho. Japanese journal of clinical medicine.

[193]  W. Muller,et al.  Novel activating mutations in the neu proto-oncogene involved in induction of mammary tumors. , 1994, Molecular and Cellular Biology.

[194]  E. Gelmann,et al.  erbB-2 antisense oligonucleotides inhibit the proliferation of breast carcinoma cells with erbB-2 oncogene amplification. , 1994, British Journal of Cancer.

[195]  B. Groner,et al.  NIH/3T3 cells transformed with the activated erbB-2 oncogene can be phenotypically reverted by a kinase deficient, dominant negative erbB-2 variant , 1994, Molecular and Cellular Endocrinology.

[196]  M. Hung,et al.  Nuclear localization of p185neu tyrosine kinase and its association with transcriptional transactivation. , 1994, Biochemical and biophysical research communications.

[197]  N. Hynes,et al.  Intracellular expression of single chain antibodies reverts ErbB-2 transformation. , 1994, The Journal of biological chemistry.

[198]  L. Cantley,et al.  ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor , 1994, Molecular and cellular biology.

[199]  W. Gullick,et al.  Identification of c‐erbB‐3 binding sites for phosphatidylinositol 3′‐kinase and SHC using an EGF receptor/c‐erbB‐3 chimera. , 1994, The EMBO journal.

[200]  M. Sliwkowski,et al.  Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin. , 1994, The Journal of biological chemistry.

[201]  M. Kraus,et al.  Efficient coupling with phosphatidylinositol 3-kinase, but not phospholipase C gamma or GTPase-activating protein, distinguishes ErbB-3 signaling from that of other ErbB/EGFR family members , 1994, Molecular and cellular biology.

[202]  W. Muller,et al.  Mammary tumors expressing the neu proto-oncogene possess elevated c-Src tyrosine kinase activity , 1994, Molecular and cellular biology.

[203]  G. Plowman,et al.  Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[204]  D. Barnes,et al.  Expression of the ERBB3 gene product in breast cancer. , 1992, British Journal of Cancer.

[205]  R. Cardiff,et al.  Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[206]  D. Slamon,et al.  Transformation mediated by the human HER-2 gene independent of the epidermal growth factor receptor. , 1992, Oncogene.

[207]  G. Staal,et al.  Characterization of protein tyrosine kinases from human breast cancer: involvement of the c-src oncogene product. , 1992, Cancer research.

[208]  D. Pinkel,et al.  ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[209]  B. Ljung,et al.  The HER2 (c-erbB-2) oncogene is frequently amplified in in situ carcinomas of the breast. , 1992, Oncogene.

[210]  M. Lindstrom,et al.  Frequent induction of mammary carcinomas following neu oncogene transfer into in situ mammary epithelial cells of susceptible and resistant rat strains. , 1991, Cancer research.

[211]  C. Cordon-Cardo,et al.  Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. , 1990, Oncogene.

[212]  H. Roels,et al.  The subcellular localization of the neu protein in human normal and neoplastic cells , 1989, International journal of cancer.

[213]  M. Kraus,et al.  Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumors. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[214]  D. Weiner,et al.  Linkage of tyrosine kinase activity with transforming ability of the p185neu oncoprotein. , 1989, Oncogene.

[215]  P. Jolicoeur,et al.  Stochastic appearance of mammary tumors in transgenic mice carrying the MMTV/c-neu oncogene , 1989, Cell.

[216]  D. Weiner,et al.  A point mutation in the neu oncogene mimics ligand induction of receptor aggregation , 1989, Nature.

[217]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[218]  S. Aaronson,et al.  Different structural alterations upregulate in vitro tyrosine kinase activity and transforming potency of the erbB-2 gene , 1988, Molecular and cellular biology.

[219]  P. Leder,et al.  Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene , 1988, Cell.

[220]  A. Ullrich,et al.  Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[221]  W. Gullick,et al.  OVEREXPRESSION OF THE c-erbB-2 ONCOPROTEIN IN HUMAN BREAST CARCINOMAS: IMMUNOHISTOLOGICAL ASSESSMENT CORRELATES WITH GENE AMPLIFICATION , 1987, The Lancet.

[222]  C R King,et al.  erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. , 1987, Science.

[223]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[224]  M. Melamed,et al.  Expression of epidermal growth factor receptor in human cultured cells and tissues: relationship to cell lineage and stage of differentiation. , 1986, Cancer research.

[225]  T. Yamamoto,et al.  The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. , 1986, Science.

[226]  Cori Bargmann,et al.  Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185 , 1986, Cell.

[227]  R. Weinberg,et al.  The neu gene: an erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor. , 1985, Science.

[228]  C R King,et al.  Amplification of a novel v-erbB-related gene in a human mammary carcinoma. , 1985, Science.

[229]  R. Weinberg,et al.  The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen , 1984, Nature.

[230]  R. Weinberg,et al.  Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts , 1981, Nature.